Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin

Journal:Thrombosis and Haemostasis
ISSN:0340-6245
DOI:http://dx.doi.org/10.1160/TH08-10-0675
Issue:2009: 101/4 (Apr) pp. 605-794
Pages:665-673

Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin

Cristina Rodríguez*; María González-Díez*; Lina Badimon; José Martínez-González
Centro de Investigación Cardiovascular (CSIC-ICCC), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Summary

Sphingosine-1-phosphate (S1P) is a bioactive lipid generated in the intracellular membranes from the metabolism of sphingomyelin. Once secreted/exported by cells of haematopoietic origin and vascular cells S1P interacts with plasma proteins and accumulates in high-density lipoprotein (HDL). Growing evidence indicates that HDL-associated S1P is responsible for the beneficial effects of these lipoproteins on vasorelaxation, cell survival, cell adhesiveness, angiogenesis and synthesis of two powerful endogenous anti-atherogenic and anti-thrombotic molecules such as nitric oxide (NO) and prostacyclin (PGI2). It is likely that vascular effects of HDL-S1P are regulated by the local expression of S1P receptors. Five G protein-coupled receptors (S1P1 to S1P5), with differential expression patterns and dissimilar coupling mechanism to G protein subunits, have been identified in the vasculature. This review is focused on the central role of S1P as a bioactive component that confers vasculoprotective properties to HDL by eliciting a wide range of biological responses on endothelial and smooth muscle cells largely dependent on the up-regulation of NO and prostacyclin.

Keywords

prostacyclin, nitric oxide, vascular function, High-density lipoproteins, sphingosine-1-phosphate

DOI

http://dx.doi.org/10.1160/TH08-10-0675

You may also be interested in...

1.

Petra Kleinbongard, Stefanie Keymel, Malte Kelm

Thrombosis and Haemostasis 2007 98 5: 970-974

http://dx.doi.org/10.1160/TH07-04-0305

2.

Gemma Vilahur, Esther Pena, Teresa Padró, Lina Badimon

Thrombosis and Haemostasis 2007 97 4: 650-657

http://dx.doi.org/10.1160/TH06-11-0652

3.

Paolo Gresele1, Rino Migliacci1, Alessandra Procacci1, Paola De Monte1, Erminio Bonizzoni2

Thrombosis and Haemostasis 2007 97 3: 444-450

http://dx.doi.org/10.1160/TH06-10-0555



Articles

You've 211 Article(s) in your Basket.

TH 107.5

Clinical Focus on GPIIb/IIIa inhibitors: In the May issue of Thrombosis and Haemostasis Armstrong...

TH 107.4

The April 2012 issue of Thrombosis and Haemostasis TH 107.4 is a Theme Issue by A. Schober, T....

Thrombosis and Haemostasis official organ of Spanish Society for Thrombosis and Haemostasis

Thrombosis and Haemostasis, founded in 1957, has become the official organ of the Spanish Society...